PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 22 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
n-hexane and aqueous seed extracts significantly reduced paw edema (45.09% and 60.79% respectively) and lowered C-Reactive Protein and WBC levels in CFA-induced rat models [PMID:37005957].
Seed extracts markedly reduced seizure activity in pentylenetetrazole-induced kindling mice [PMID:37064443].
Crude extract produced a dose-dependent decrease in systemic arterial blood pressure and heart rate in anesthetized rats [PMID:23194619].
A polyherbal extract containing C. absus dose-dependently improved glycometabolic control in alloxan-induced diabetic rats [PMID:38234664].
Seed extracts exhibited anti-nociceptive and anti-inflammatory potential in Wistar rats via protein denaturation and carrageenan-induced paw edema models [PMID:36861232].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 28872683 (2018) — Phytochemistry and pharmacological potential of Cassia absus - a review. · The Journal of pharmacy and pharmacology
- 2.PMID: 23194619 (1996) — Traditional medicine Cassia absus L. (chaksu)-pharmacological evaluation. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 3.PMID: 37064443 (2023) — Assessment of in vivo antiepileptic potential and phytochemical analysis of Cassia absus seed extracts. · Heliyon
- 4.PMID: 27538998 (2016) — A Review of Flavonoids from Cassia Species and their Biological Activity. · Current pharmaceutical biotechnology
- 5.PMID: 37005957 (2023) — Cassia absus-mediated upregulation of IL-4, IL-10 and downregulation of IL-1β, IL-6, TNF- α, NF-κB, IFN-γ in CFA-induced arthritis model.